The Children's Tumor Foundation (CTF) is supporting the addition of a new treatment arm to the INTUITT-NF2 platform clinical trial, an innovative clinical trial designed to accelerate the development of therapies for people living with NF2-related schwannomatosis (NF2-SWN).
This new arm will evaluate a combination of retifanlimab and bevacizumab, bringing immunotherapy into the growing pipeline of treatments being tested for NF2-related tumors. The drug retifanlimab has been donated by Incyte, enabling the combination to move forward within the clinical trial's framework.
Together, these therapies target two different aspects of tumor biology: bevacizumab blocks VEGF, a signal tumors use to grow new blood vessels, while retifanlimab activates the immune system by releasing a molecular "brake" that normally prevents immune cells from attacking tumors.
A Platform Trial Designed to Move Faster
The INTUITT-NF2 platform trial represents a fundamentally different way to test treatments for rare diseases.
Instead of launching a new clinical trial for every potential therapy, the INTUITT trial maintains a standing trial infrastructure that can add new treatment arms as promising drugs emerge. This adaptive platform-basket trial allows researchers to evaluate multiple therapies simultaneously in patients with NF2-related tumors-including vestibular schwannomas, non-vestibular schwannomas, meningiomas, and ependymomas.
For rare diseases like NF2-SWN, where patient populations are limited, this approach offers major advantages:
Trials can open faster
Multiple drugs can be evaluated in parallel
Promising treatments can move forward more quickly
Each treatment arm typically enrolls up to 40 participants, allowing researchers to assess tumor response, safety, hearing outcomes, quality of life, and biological markers that reveal how the therapy is working.
Early Success Demonstrates the Model
Earlier this year, the National Comprehensive Cancer Network (NCCN) included brigatinib as a recommended treatment option for NF2-SWN. That milestone grew out of research that identified brigatinib as a promising therapy and tested it through the INTUITT-NF2 platform. It shows how the trial can move a potential treatment from research into guidance clinicians use when considering care.
Results from the brigatinib arm, published in The New England Journal of Medicine, showed that 23% of tumors evaluated had a measurable response, including 10% of the tumors designated as the study's primary targets. Hearing improved in 35% of eligible ears. For people facing limited treatment options and the possibility of hearing loss, those findings marked meaningful progress.
The platform continues to build on that progress. Another arm is evaluating neratinib across multiple NF2-related tumor types, while the new retifanlimab-bevacizumab arm will test a different treatment strategy.
A New Strategy: Combining Immunotherapy and Anti-VEGF Therapy
The newly funded arm of INTUITT will test whether combining immunotherapy with VEGF inhibition can produce stronger or more durable responses.
In this arm, approximately 40 participants may receive retifanlimab together with bevacizumab. Enrollment will occur in stages: an initial group of 20 participants will be enrolled first. If early results show a promising treatment signal, meaning evidence that the therapy may be benefiting patients with an acceptable safety profile, the trial will expand to enroll 20 additional participants.
Tumor shrinkage measured through imaging
Changes in hearing ability for vestibular schwannoma patients
Patient-reported quality of life
Biological markers that reveal how the therapy is affecting tumors
Researchers will also carefully monitor safety and tolerability throughout the study.
This combination strategy builds on emerging research suggesting that blocking VEGF may reshape the tumor environment in ways that allow immune cells to more effectively recognize and attack tumor cells.
Building the NF2 Treatment Pipeline
The addition of the retifanlimab-bevacizumab arm reflects the broader strategy behind CTF's NF Therapeutics Accelerator campaign: to identify promising therapies and move them rapidly into clinical testing.
CTF is actively working with researchers, pharmaceutical partners, and the INTUITT leadership team to bring additional compounds into the trial. Several potential future therapies-including new targeted drugs and immune-based approaches-are already under discussion.
By maintaining a standing platform capable of testing multiple therapies at once, INTUITT is helping transform how treatments are developed for NF2-related schwannomatosis.
Instead of waiting years for new trials to launch, promising therapies can now enter an existing clinical infrastructure, bringing potential new options to patients faster.
This new treatment arm represents another step toward that goal: expanding the NF2 treatment pipeline and continuing the search for therapies that can control tumors while preserving hearing and quality of life for people living with NF2-SWN.